These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

26 related articles for article (PubMed ID: 3247592)

  • 1. Head-to-head comparison of H2-receptor antagonists and proton pump inhibitors in the treatment of erosive esophagitis: a meta-analysis.
    Wang WH; Huang JQ; Zheng GF; Xia HH; Wong WM; Lam SK; Wong BC
    World J Gastroenterol; 2005 Jul; 11(26):4067-77. PubMed ID: 15996033
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nocturnal gastric acid secretion: its importance in the pathophysiology and rational therapy of duodenal ulcer.
    De Gara CJ; Gledhill T; Hunt RH
    Scand J Gastroenterol Suppl; 1986; 121():17-24. PubMed ID: 3532294
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Idiopathic gastric acid hypersecretion: treatment implications for refractory acid/peptic disorders.
    Lewis JH
    Aliment Pharmacol Ther; 1991; 5 Suppl 1():15-24. PubMed ID: 1888834
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Gastric secretion and reflux pattern in reflux oesophagitis before and during ranitidine treatment.
    Johansson KE; Tibbling L
    Scand J Gastroenterol; 1986 May; 21(4):487-92. PubMed ID: 3523741
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Single nocturnal dose of an H2 receptor antagonist for the treatment of duodenal ulcer.
    Gledhill T; Howard OM; Buck M; Paul A; Hunt RH
    Gut; 1983 Oct; 24(10):904-8. PubMed ID: 6311692
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Influence of the timing of administration of 300 mg ranitidine on 24-hour gastric pH in patients acute duodenal ulcer.
    Cortot A; Guillemot F; Moreau J; Soule JC; Veyrac M; Alberola B; Pappo M
    Aliment Pharmacol Ther; 1992 Aug; 6(4):487-93. PubMed ID: 1420740
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Time of administration influences gastric inhibitory effects of ranitidine.
    Johnston DA; Wormsley KG
    Scand J Gastroenterol; 1988 Nov; 23(9):1137-40. PubMed ID: 3247592
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Omeprazole: a pharmacoeconomic evaluation of its use in duodenal ulcer and reflux oesophagitis.
    Barradell LB; McTavish D
    Pharmacoeconomics; 1993 Jun; 3(6):482-510. PubMed ID: 10146883
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Acid secretory changes and early relapse following duodenal ulcer healing with ranitidine or sucralfate.
    Marks IN; Johnston DA; Young GO
    Am J Med; 1991 Aug; 91(2A):95S-101S. PubMed ID: 1882911
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Therapy with H2 receptor antagonists in childhood. Use of ranitidine in duodenal and gastric ulcer and reflux esophagitis].
    Bender SW
    Fortschr Med; 1992 Nov; 110(33):629-32. PubMed ID: 1478605
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pantoprazole. A review of its pharmacological properties and therapeutic use in acid-related disorders.
    Fitton A; Wiseman L
    Drugs; 1996 Mar; 51(3):460-82. PubMed ID: 8882382
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Effects of gastric acid secretion inhibition on intrinsic factor secretion and cobalamin absorption].
    Belaïche J
    Gastroenterol Clin Biol; 1991; 15(5 ( Pt 2)):109C-115C. PubMed ID: 1916113
    [No Abstract]   [Full Text] [Related]  

  • 13.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 14.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 15.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 16.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 17.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 18.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 2.